Core Essential Genes in Primary Effusion Lymphoma Cell Lines
原发性渗出性淋巴瘤细胞系的核心必需基因
基本信息
- 批准号:9203705
- 负责人:
- 金额:$ 20.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeB-Cell LymphomasB-LymphocytesBiologyCRISPR screenCRISPR/Cas technologyCell LineCell ProliferationCell SurvivalCellsCellular biologyClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsDataData AnalysesData SetDiseaseEligibility DeterminationEssential GenesEtiologyFutureGene ExpressionGenesGoalsHerpesviridaeHumanHuman Cell LineHuman Herpesvirus 8IRF4 geneIndividualKnock-outLaboratoriesLinkLymphomaMalignant NeoplasmsMediatingMethodsMutationNon-Hodgkin&aposs LymphomaNormal CellOncogenicPathway interactionsPatientsPositioning AttributeRiskRoleSolidSomatic MutationSpermidine SynthaseStagingSystemTCF3 geneTechnologyValidationViral OncogeneVirusVirus DiseasesWorkaddictionbasecell transformationcomputerized toolsdata miningeffusionfollow-upgenome editinggenome-widemammalian genomenew therapeutic targetnovelprimary effusion lymphomaresearch studyscreeningtooltranscription factortreatment strategytumortumorigenesis
项目摘要
Summary
Kaposi's sarcoma-associated herpesvirus (KSHV) is a human herpesvirus that causes
primary effusion B cell lymphoma (PEL), particularly in patients with acquired
immunodeficiency syndrome (AIDS). PEL tumorigenesis is largely driven by the
interference of viral oncogenes with normal cell biology. Accordingly, KSHV-positive PEL
derived cell lines require continued viral infection for their survival and proliferation in
culture. The specific cellular genes and pathways required for KSHV to cause
lymphomas, however, are not fully known. In the last two years, efficient methods for
gene editing in human cell lines have become available and have been adapted for
genome-scale knock-out screens. We have conducted genome-wide CRISPR/Cas9-
mediated knockout screens to comprehensively identify cellular genes and pathways
necessary for KSHV-induced PEL cell survival and proliferation. In Aim 1, we propose to
identify and validate a core set of genes required for the survival of PEL cell lines. In Aim
2, we propose to focus on the biology of a set of functionally related genes that were
identified as essential for PEL cell survival and proliferation in our preliminary
CRISPR/Cas9 screen. The proposed work for Aim 2 includes the in depth validation of
the requirement of these genes for PEL cell survival and proliferation, and experiments
to investigate how these genes collaborate in a gene expression cascade. Together,
these aims are expected to result in a comprehensive overview of key players in KSHV-
mediated B cell transformation and may identify new drug targets.
总结
卡波西肉瘤相关疱疹病毒(KSHV)是一种人类疱疹病毒,
原发性渗出性B细胞淋巴瘤(PEL),特别是在获得性
免疫缺陷综合征(艾滋病)。PEL肿瘤发生在很大程度上由
病毒癌基因对正常细胞生物学的干扰。因此,KSHV阳性PEL
衍生的细胞系需要持续的病毒感染以使它们在细胞中存活和增殖。
文化KSHV所需的特定细胞基因和途径导致
然而,淋巴瘤并不完全清楚。在过去的两年里,
人类细胞系中的基因编辑已经变得可用,并且已经适应于
基因组规模的敲除筛选。我们进行了全基因组CRISPR/Cas9-
介导的敲除筛选,以全面鉴定细胞基因和途径
KSHV诱导的PEL细胞存活和增殖所必需的。在目标1中,我们建议
鉴定和验证PEL细胞系存活所需的核心基因组。在Aim中
2,我们建议专注于一组功能相关基因的生物学,这些基因是
在我们的初步研究中,
CRISPR/Cas9筛选。目标2的拟议工作包括深入验证
这些基因对于PEL细胞存活和增殖的需要,以及实验
来研究这些基因如何在基因表达级联中协作。我们一起努力,
这些目标预计将导致对KSHV关键参与者的全面概述-
介导的B细胞转化,并可能确定新的药物靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eva Henriette Gottwein其他文献
Eva Henriette Gottwein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eva Henriette Gottwein', 18)}}的其他基金
Mechanisms of KSHV-induced endothelial cell loss of contact inhibition of proliferation
KSHV诱导内皮细胞失去接触抑制增殖的机制
- 批准号:
10762813 - 财政年份:2023
- 资助金额:
$ 20.16万 - 项目类别:
KSHV-induced oncogenic changes in a primary human lymphatic endothelial cell model of Kaposi's Sarcoma
KSHV 诱导的卡波西肉瘤原代人淋巴内皮细胞模型的致癌变化
- 批准号:
10327223 - 财政年份:2021
- 资助金额:
$ 20.16万 - 项目类别:
KSHV-induced oncogenic changes in a primary human lymphatic endothelial cell model of Kaposi's Sarcoma
KSHV 诱导的卡波西肉瘤原代人淋巴内皮细胞模型的致癌变化
- 批准号:
10457488 - 财政年份:2021
- 资助金额:
$ 20.16万 - 项目类别:
Transcriptional Control of Cellular Survival and Proliferation in KSHV-transformed B Cells
KSHV 转化的 B 细胞中细胞存活和增殖的转录控制
- 批准号:
10012433 - 财政年份:2020
- 资助金额:
$ 20.16万 - 项目类别:
Transcriptional Control of Cellular Survival and Proliferation in KSHV-transformed B Cells
KSHV 转化的 B 细胞中细胞存活和增殖的转录控制
- 批准号:
10380596 - 财政年份:2020
- 资助金额:
$ 20.16万 - 项目类别:
Transcriptional Control of Cellular Survival and Proliferation in KSHV-transformed B Cells
KSHV 转化的 B 细胞中细胞存活和增殖的转录控制
- 批准号:
10524178 - 财政年份:2020
- 资助金额:
$ 20.16万 - 项目类别:
Transcriptional Control of Cellular Survival and Proliferation in KSHV-transformed B Cells
KSHV 转化的 B 细胞中细胞存活和增殖的转录控制
- 批准号:
10608096 - 财政年份:2020
- 资助金额:
$ 20.16万 - 项目类别:
Core Essential Genes in Primary Effusion Lymphoma Cell Lines
原发性渗出性淋巴瘤细胞系的核心必需基因
- 批准号:
9277430 - 财政年份:2016
- 资助金额:
$ 20.16万 - 项目类别:
Kaposi's Sarcoma-associated Herpesvirus Mimics of Cellular microRNAs
卡波西肉瘤相关疱疹病毒的细胞 microRNA 模拟物
- 批准号:
8997993 - 财政年份:2014
- 资助金额:
$ 20.16万 - 项目类别:
Kaposi's Sarcoma-associated Herpesvirus Mimics of Cellular microRNAs
卡波西肉瘤相关疱疹病毒的细胞 microRNA 模拟物
- 批准号:
8732118 - 财政年份:2014
- 资助金额:
$ 20.16万 - 项目类别:
相似海外基金
Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
- 批准号:
24K19213 - 财政年份:2024
- 资助金额:
$ 20.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
- 批准号:
23K15982 - 财政年份:2023
- 资助金额:
$ 20.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
- 批准号:
10606730 - 财政年份:2023
- 资助金额:
$ 20.16万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10566833 - 财政年份:2023
- 资助金额:
$ 20.16万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10987699 - 财政年份:2023
- 资助金额:
$ 20.16万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10541285 - 财政年份:2022
- 资助金额:
$ 20.16万 - 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10540952 - 财政年份:2022
- 资助金额:
$ 20.16万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10703446 - 财政年份:2022
- 资助金额:
$ 20.16万 - 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
- 批准号:
22K08497 - 财政年份:2022
- 资助金额:
$ 20.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10707312 - 财政年份:2022
- 资助金额:
$ 20.16万 - 项目类别: